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Abstract 
In view of the clinical need for new anti-epileptic drugs (AEDs) with novel modes of action, we 
used a zebrafish seizure model to screen the anticonvulsant activity of medicinal plants used for 
traditional epilepsy treatment in the Congo, identifying 4 crude plant extracts that inhibited 
pentylenetetrazol (PTZ)-induced seizures in zebrafish larvae. Zebrafish bioassay-guided 
fractionation of an anticonvulsant Fabaceae species, Indigofera arrecta, identified indirubin, an 
bis-indole alkaloid with known inhibitory activity at glycogen synthase kinase (GSK)-3, a well 
known protein kinase.  
Target validation experiments with partial loss of function of GSK-3 via antisense knockdown in 
zebrafish showed anticvonvulant activity against PTZ-induced seizures. Subsequently, indirubin, 
together with the more potent and GSK-3 specific derivative 6-bromoindirubin-3'-oxime (BIO-
acetoxime) and the structurally unrelated GSK-3β inhibitor 2-methyl-5-[3-[4-
(methylsulfinyl)phenyl]-5-benzofuranyl]-1,3,4-oxadiazole (TCS2002), were tested in zebrafish 
and rodent seizure assays. All 3 compounds revealed anticonvulsant activity in PTZ-treated 
zebrafish larvae, with electroencephalographic recordings revealing reduction of epileptiform 
discharges. All 3 compounds also showed anticonvulsant activity in the pilocarpine rat model for 
limbic seizures and in the 6-Hz psychomotor refractory seizure mouse model. Moreover, BIO-
acetoxime, the most potent GSK-3 inhibitor was also able to exert anticonvulsant actions in 6-Hz 
fully kindled mice.  
Our findings provide the first evidence for anticonvulsant activity of selective GSK-3 inhibitors, 
thereby implicating GSK-3 as a potential new drug target for epilepsy. Our results also support the 
use of zebrafish bioassay-guided fractionation of anti-epileptic medicinal plant extracts as an 
effective strategy for the discovery of new AEDs with novel mechanisms of action.
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Introduction 
Despite the availability of over 25 approved anti-epileptic drugs (AEDs), epilepsy remains an 
indication with an urgent medical need for new therapeutics, and there are still significant 
challenges in the field of AED discovery (Bialer and White, 2010; Simonato et al., 2012).  
Most AEDs developed in the past two decades – despite their ability to offer improved therapeutic 
options for a wide range of epileptic seizures – do not address the problem of pharmacoresistant 
epilepsy, nor are they able to prevent or cure epilepsy. One third of all epilepsy patients – about 
15-20 million patients worldwide – do not adequately respond to any of the existing AEDs, and 
comorbidities still impose a major burden on their quality of life. 
Natural products and their analogues have historically been of considerable value for the discovery 
and development of pharmaceuticals in numerous indications including epilepsy (Cragg and 
Newman, 2013). In many developing countries these natural products, derived from animals, 
plants or microbes, are still routinely used to treat epileptic seizures and have therefore inspired 
many researchers (Moshi et al., 2005). To explore this potential of medicinal plants for the 
discovery of novel  AEDs, we recently initiated an effort to identify, using zebrafish seizure models 
as in vivo bioassays, the anti-epileptic constituents of medicinal plants used for the treatment of 
epileptic seizures in the Democratic Republic of the Congo.  
Over the past decade, the zebrafish has been established as a valuable tool to understand 
mechanisms involved in the development of epilepsy and to screen for compounds with 
anticonvulsant activity in a medium- to high-throughput manner (Baraban et al., 2007; Baraban 
and Löscher, 2014; Baraban et al., 2005). Using both genetic and pharmacological models, 
zebrafish models of epilepsy have been shown to share many similarities with their corresponding 
rodent models, including seizure-like behavior, epileptic discharges, increased c-fos expression in 
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the brain and similar responses to AEDs in terms of anticonvulsant activity (Afrikanova et al., 
2013; Hortopan et al., 2010; Schubert et al., 2014; Suls et al., 2013; Vermoesen et al., 2011). 
We and others have recently established zebrafish as a platform for biodiscovery (identification of 
bioactive natural products) (Bohni et al., 2013; Challal et al., 2012; Crawford et al., 2008; 
Crawford et al., 2011). By screening crude methanolic plant extracts in zebrafish seizure models, 
we have been able to experimentally validate in vivo the anticonvulsant activity of medicinal plants 
used by traditional healers for the treatment of seizures in human patients. Furthermore, by using 
these same zebrafish seizure models for in vivo bioassay-guided fractionation, we have been able 
to isolate several anticonvulsant secondary metabolites from these extracts, including bisabolene 
sesquiterpenoids from the Ayurvedic medicinal plant Curcuma longa (Orellana-Paucar et al., 
2012), tanshinones from the Chinese medicinal plant Salvia miltiorrhiza (Buenafe et al., 2013) and 
spirostane glycosides from the Philippine medicinal plant Solanum torvum (Challal et al., 2014). 
Here, we report the identification of the glycogen synthase kinase (GSK)-3 inhibitor indirubin as 
a novel anticonvulsant from the Congolese medicinal plant Indigofera arrecta. As GSK-3, a 
protein kinase that exists in two isoforms (GSK-3α and GSK-3β) has not previously been reported 
as a drug target for epilepsy, we investigated the anticonvulsant activity of additional kinase 
inhibitors, with higher potency and higher specificity for GSK-3, in both zebrafish and rodent 
seizure models. 
 
 
Methods 
Zebrafish 
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Zebrafish (Danio rerio) with an AB genetic background were maintained at 28.5°C, on a 14/10 
hour light/dark cycle under standard aquaculture conditions, and fertilized eggs were collected via 
natural spawning. Embryos were reared under constant light conditions in 0.3x Danieau's buffer 
(also referred to in text simply as ‘embryo medium’ - 1.5 mM HEPES, pH 7.6, 17.4 mM NaCl, 
0.21 mM KCl, 0.12 mM MgSO4, and 0.18 mM Ca(NO3)2) in an incubator at 28.5°C. For the 
behavioral and electrographic assays, larvae of 7 days post fertilization (dpf) of the Fli strain were 
used. In our experimental setup, we found that larvae displayed the most consistent basal activity 
levels when raised under constant light conditions. For the morpholino (MO) injections, embryos 
of the AB line were used. 
 
Bioassay-guided isolation of indirubin 
The leaves of I. arrecta and other plant material were collected on Idjwi Island, Lake Kivu (Congo) 
and dried. For the testing in zebrafish, dried plant material was extracted with methanol. After 
centrifugation the clear supernatants were collected and concentrated using a rotavapor (Buchi 
Labortechnik, Hendrik-Ido-Ambacht, The Netherlands). The extract was suspended in DMSO 
before use (final concentration of 20 mg/ml). For isolation of the active constituent of I. arrecta 
the dried plant material was extracted multiple times with acetone. The extracts were combined, 
evaporated to dryness under reduced pressure on kieselguhr as a sorbent, and the resulting powder 
applied to the top of a silica gel 60 column. The fractionation was performed by liquid 
chromatography with ethylacetate as the mobile phase. Fractions containing the bio-active 
constituent were pooled and  dried. The residue was dissolved in dichloromethane by heating and 
stored at 4°C overnight. The precipitate formed contained the active constituent and was collected. 
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Purity was determined by HPLC (diol column, mobile phase: ethylacetate) and was 85% (as 
monitored at UV289). 
 
Behavioral analysis of anticonvulsant activity in zebrafish 
Six dpf larvae were placed in a 96-well plate with one larva per well. The larvae were pre-incubated 
with compound or vehicle for 18 hours in a volume of 100 μl. The concentrations of compound 
used are described in the results section, final concentration of DMSO was always 1% w/v. After 
pre-incubation with each compound, normal embryo medium was added to twelve of the twenty-
four larvae per treatment group. To the other twelve larvae, 100 μl of PTZ solution was added to 
obtain a final concentration of 20 mM (Berghmans et al., 2007; Orellana-Paucar et al., 2012). 
Larvae were allowed to habituate for 5 min in a darkened chamber of an automated tracking device 
(ZebraBox, Viewpoint, France). The total locomotor activity was then measured using an 
automated tracking system (VideoTrack, Viewpoint, France) (Orellana-Paucar et al., 2012). Total 
movement or activity was expressed in “actinteg” units. The actinteg value of Viewpoint software 
is defined as the sum of all image pixel changes detected during the time window defined for the 
experiment. 
 
Electroencephalographic analysis of anticonvulsant activity in zebrafish 
Each larva (6 dpf) was pre-incubated with either compound or vehicle for 18 hours in a volume of 
400 μl in individual wells of a 24-well plate. After the pre-incubation time, an equal volume of 
PTZ solution was added to the well to obtain a final concentration of 20 mM. After exposure for 
15 minutes  the larva was embedded in 2% low-melting-point agarose, a glass electrode filled with 
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artificial cerebrospinal fluid composed of (mM): 124 NaCl, 2 KCl, 2 MgSO4, 2 CaCl2, 1.25 
KH2PO4, 26 NaHCO3 and 10 glucose (resistance 1-5 MΩ) was placed into the optic tectum and 
recording was performed in current clamp mode, low-pass filtered at 1 kHz, high-pass filtered 0.1 
Hz, digital gain 10, sampling interval 10 μs (MultiClamp 700B amplifier, Digidata 1440A 
digitizer, both Axon instruments, USA). The electroencephalographic (EEG) recordings started 
each time exactly 20 minutes after proconvulsant exposure and were continued for 10 minutes. 
Recordings from three to seven larvae were taken per experimental condition. Epileptiform activity 
was analyzed according to the duration of spiking paroxysms as described previously (Orellana-
Paucar et al., 2012). Briefly, we compared the total number, the average duration and the 
cumulative duration of epileptiform discharges in treated larvae. Spikes were categorized as 
interictal-like (<3 s) or ictal-like (>3 s) (D'Antuono et al., 2010) with amplitudes exceeding three 
times the background noise with the aid of Clampfit 10.2 software (Molecular devices corporation, 
USA). 
 
Toxicological evaluation 
Zebrafish larvae were incubated with compound or vehicle in the dark. After 90 min, each larva 
was individually checked under the microscope for the following signs of acute locomotor 
impairment: hypoactivity, decreased or no touch/escape response upon a light touch of the tail with 
a fine needle (Fetcho et al., 2008; Pietri et al., 2009), loss of posture, body deformation, 
exophthalmos (bulging of the eyes out of their sockets), slow or absent heartbeat, and death. After 
an overnight incubation (18 hours), assessment of larvae for the same above-mentioned signs of 
toxicity was repeated. A larva was considered normal if it could cover a distance twice its body 
length. A shorter distance travelled or movement in the same place was scored as a decreased or 
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impaired touch response. No visible movement upon a touch stimulus was counted as no response. 
The (maximum tolerated concentration) (MTC) was thus defined as the maximum concentration 
that did not cause death and where not more than two out of 12 larvae exhibited any sign of 
locomotor impairment (including no touch response) after an 18-hour incubation period. 
 
Rodents 
All experiments were carried out according to the national guidelines on animal experimentation 
and were approved by the Ethical Committee for Animal Experiments of the Faculty of Medicine 
and Pharmacy of the Vrije Universiteit Brussel (Brussels, Belgium). The animals were kept under 
standard laboratory conditions, received food and water ad libitum and were kept on a 10/14 h 
dark/light cycle.  
 
Drugs and reagents 
Indirubin was obtained from Sigma-Aldrich Chemicals (Bornem, Belgium). BIO-acetoxime and 
TCS2002 were purchased from Tocris Bioscience (Bristol, United Kingdom), roscovitine was 
obtained from Selleckchem (Houston, USA), pilocarpine.HCl and PTZ from Sigma (St Louis, MO, 
USA). All other chemicals were analytical reagent grade and were obtained from Merck 
(Darmstadt, Germany). Aqueous solutions were prepared in fresh water purified by an arium pro 
UV system (Sartorius Stedim Biotech GmbH, Goettingen, Germany). For the in vivo microdialysis 
experiments, stock solutions were prepared in ultra purified water, diluted with modified Ringer’s 
solution (147 mM NaCl; 4 mM KCl; 2.3 mM CaCl2), previously filtered through a membrane filter 
(0.2 µm diameter) and directly delivered into the hippocampus through perfusion of the 
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microdialysis probe. Prior to their systemic administration, indirubin, BIO-acetoxime and 
TCS2002 were dissolved in propyleenglycol:saline (50:50). 
 
Animal models for epilepsy and epileptic seizures 
Male NMRI mice (25-30 g) were used to test the effect of indirubin, the GSK-3- and CDK-5 
inhibitors in the acute mouse models for epileptic seizures, including the electrical 6-Hz 
psychomotor refractory seizure model and the i.v. pilocarpine- and PTZ mouse infusion seizure 
models. NMRI mice were used since, due to their low cost, they are the preferential mouse strain 
for initial screening of drug compounds in seizure models. FVB/N mice were used to test the 
anticonvulsant effects of BIO-acetoxime in fully kindled mice. To test the anticonvulsant effects 
of our test compounds in the pilocarpine rat model, male albino Wistar rats (250-320 g) were used 
(Charles River, Chatillon-sur-Chalaronne, France). 
 
Electrically-induced 6-Hz models  
Prior to the electrical stimulation, 0.2% xylocaine was always applied to the cornea of the mice to 
induce local anesthesia and ensure good conductivity. Corneal stimulation (0.2 ms duration pulses 
at 6 Hz for 3 s) was then administered by a constant current device (ECT Unit 57800; Ugo Basil, 
Comerio, Italy). Animals are restrained manually and released immediately in a cage of plexi glas 
following the stimulation (De Bundel et al., 2011; Kaminski et al., 2004). Then, the behavior of 
the animals is observed. 
a/ Acute 6-Hz model 
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For the acute 6-Hz model, the evoked seizures are characterized by stun, forelimb clonus, twitching 
of vibrissae and/or straub-tail for at least 45s. Each animal was tested only once at a selected 
threshold current intensity. The threshold current is defined as the current necessary to elicit clear 
seizures for at least 45 s in 6 consecutive naive animals. Protection is defined as the complete 
absence of seizures or when a seizure last for maximum 45s. A minimum of six animals per 
experimental group is required. 
b/ Effect of  Bio-acetoxime in 6-Hz corneally kindled mice 
Unlike the acute 6-Hz model, the behavioral severity of the seizures in the 6-Hz kindling model 
was scored based on Racine’s scale (Racine, 1972): (1) facial twitches and chewing, (2) head 
nodding, (3) bilateral forelimb clonus, (4) rearing and (5) generalized clonus with rearing and 
falling. Mice were considered fully kindled when they have exhibited at least 10 consecutive 
generalized seizures (stages 3-5). To achieve the fully kindled state, mice were stimulated at a 
fixed subconvulsive threshold current twice daily, except the weekends, with a 4h minimum 
interval between the daily stimulations. Kindled mice were then stimulated for only 2 days a week, 
twice daily to maintain the fully kindled state. Meanwhile non-kindled mice were kept at the 
original stimulation scheme for maximum 1-2 more weeks. Hereafter, all non kindled mice were 
omitted. The anticonvulsant effect of BIO-acetoxime was then investigated in the “epileptic” 
kindled mice by stimulating these animals at the initial subconvulsive threshold current on Monday 
morning and on Monday afternoon, the animals were intraperitoneally (i.p.) injected with vehicle, 
30 minutes prior to the stimulation. Then, the mice were again stimulated once on Tuesday 
morning. On Tuesday afternoon, the mice were injected i.p. with BIO-acetoxime and were 
stimulated 30 min later. Seizure severity was then assessed using Racine's scale as previously 
described. The pre-treatment scores, calculated as the mean of the scores obtained during 
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maintenance of the kindled state, were compared with the post-treatment scores, obtained after the 
treatment on Tuesday. To confirm any observed effects, the experiment was repeated, respecting 
one week of washout. During this washout week, all mice were stimulated for two days (twice 
daily) to maintain the kindled state. Compound testing during a longer period has not been 
validated so far. This means that only one dose of BIO-acetoxime could be tested in one batch of 
kindled mice. The latter explains why the number of animals differs for each tested dose (Figure 
10). 
 
Chemically-induced models 
In vivo microdialysis in rats 
Microdialysis in rat hippocampus and corresponding seizures severity assessment were performed 
as previously described (Aourz et al., 2011; Aourz et al., 2014). Briefly, a microdialysis probe 
(CMA 12; CMA Microdialysis) with a membrane length of 3 mm was implanted stereotactically 
in the right hippocampus and was continuously perfused with modified Ringer’s solution at a 
constant flow rate of 2 µL/min (CMA 100 microdialysis pump, CMA Microdialysis). Seizure 
severity was assessed using a scoring system derived from Racine’s scale (Racine, 1972). This 
system consists of six stages: (0) normal activity; (1) mouth and facial movements, hyperactivity, 
grooming, sniffing, scratching, wet dog shakes; (2) head nodding, staring, tremor; (3) forelimb 
clonus, forelimb extension; (4) rearing, salivating; (5) falling. The total seizure severity score 
(TSSS) for each animal was calculated as the sum of the highest seizure severity score (SSS) 
attained in each of the 7 collection periods following the start of pilocarpine administration, and 
was used as a measure of seizure severity.  
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The protocols differed between these experimental groups as depicted in Figure 4A, Figure 6B and 
Figure 9A.  
Timed  intravenous (i.v.)  infusion seizure tests in mice 
The threshold for different phases of PTZ- or pilocarpine-induced seizure activity was determined 
by i.v. infusion of PTZ (7.5 mg/ml) or pilocarpine (24 mg/ml) in the lateral tail vein at a constant 
rate of 150 µl/min. Methylscopolamine (1 mg/kg, s.c.) was injected 30 min before pilocarpine 
infusion to prevent peripheral cholinergic symptoms. During the experiment, the animal could 
freely move in a plexi glas cage. The following end points were used to determine the seizure 
threshold. For PTZ, the endpoints were (1) first myoclonic twitch, (2) forelimb clonus, (3) falling 
(loss of righting reflexes), (4) tonic hindlimb extension (THE) and (5) death. For pilocarpine, the 
end points were (1) excessive salivation, (2) shivering, (3) rearing, (4) THE and (5) death. Time 
was measured from the start of the infusion until the onset of these different stages. Seizure 
thresholds were determined for each animal according to the following equation: chemoconvulsant 
threshold dose (mg/kg) = (infusion rate (ml/s) x chemoconvulsant drug concentration (mg/ml) x 
infusion duration (s) x 1000) / weight of mouse (g). 
 
Beamwalking assay 
The beamwalking assay was used to discover possible adverse effects such as problems with motor 
coordination or sedation, induced by the administration of indirubin. C57Bl/6 mice were trained 
to walk from a start platform along a ruler towards a closed box. The trained mice were 
administered compound or vehicle and were again tested on the beam. Mice that fell were returned 
to the position they fell from, with a maximum time of 60 s allowed on the beam. Measurements 
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that were taken are time on beam, the number of foot slips (one or both hind limbs) and the number 
of falls (Stanley et al., 2005). 
 
Statistical analysis 
Statistical analyses were performed using GraphPad Prism 4.0 software package for Windows. For 
clarity of presentation, the results obtained in the acute 6-Hz corneal model are expressed as the % 
of protected animals versus % of non-protected animals. To test any significant differences 
between the experimental groups in the acute 6-Hz model, the chi square test for trend was used. 
This test was followed by the Fisher's exact test to denote any significant differences between the 
experimental test groups and the untreated sham group. All other data are expressed as the mean 
value ± SEM. One-way ANOVA, followed by the Bonferroni’s post hoc test was used to compare 
the mean TSSSs obtained obtained in the focal pilocarpine rat model and to compare the different 
seizure thresholds in the mouse i.v. models. To compare pre- and post-treatment seizure severity 
scores in the 6-Hz corneally kindled FVB/N mice, a Mann-Withney test was used. For all statistical 
analysis  was set at 0.05.  
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Results 
Zebrafish bioassay-guided assays identified indirubin as the bioactive component of the 
medicinal plant kasholoza 
On Idjwi, an island in Lake Kivu in the Eastern Congo, traditional healers use a decoction of 14 
medicinal plants to treat patients with seizures. We sought to identify potentially novel 
anticonvulsant compounds in this mixture by screening methanolic extracts of its individual 
medicinal plants using a larval zebrafish seizure assay based on the GABAA antagonist PTZ. An 
extract of the leaves of I. arrecta, a large shrub belonging to the Fabaceae family and locally 
referred to as “kasholoza”, exhibited potent anticonvulsant activity (Figure 1A, extract 3). To 
isolate and identify the secondary bioactive metabolites of the plant (Figure 1B-1C), bioassay-
guided fractionation and structural elucidation was performed using high-resolution mass 
spectrometry and (nuclear magnetic resonance) NMR, resulting in the identification of indirubin. 
The spectral data were in agreement with those previously reported for indirubin (Figure 2) (Cuong 
et al., 2010; Hu et al., 2008; Liau et al., 2007). 
 
Indirubin exerts anticonvulsant effects in the absence of gross locomotor disturbances or 
sedation 
Our results showed that 300 µM indirubin (Figure 3A) significantly decreased larval locomotor 
activity induced by PTZ in the behavioral zebrafish assay (Figure 3B), while treatment with 30 μM 
and 100 μM did not result in a significant reduction of larval movement.  
To confirm the seizure-suppressing activity of indirubin, we performed tectal field recordings on 
zebrafish larvae as previously described (Afrikanova et al., 2013; Baraban et al., 2005). EEG 
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recordings showed that 300 μM indirubin decreased the number of interictal and ictal-like spikes 
as well as the total cumulative duration of epileptiform activity (Figure 3C). 
A number of rodent seizure models was then used to further confirm the anticonvulsant activity of 
indirubin as seen in the zebrafish behavioral and electrographic assays. Although 2 mg/kg and 10 
mg/kg indirubin was inactive in the PTZ and pilocarpine i.v. tail infusion mouse model (data not 
shown), these doses did clearly reduce the seizure severity in the focal pilocarpine rat model in a 
dose- dependent manner (Figure 4A, right panel). In addition, dose-dependent anticonvulsant 
actions of indirubin (10 mg/kg and 30 mg/kg) were observed in the acute 6-Hz model for refractory 
seizures in mice (53 mA stimulation current) (Figure 4B).  
To discover possible adverse effects such as motor coordination problems or sedation, the 
beamwalking assay was performed in C57Bl/6 mice. Administration of indirubin (10 mg/kg, i.p.) 
did not show any adverse effects. Total time on the beam, the number of foot slips and the number 
of falls was not different between control animals and indirubin-treated mice (Figure 5B). 
Diazepam was used as a positive control. With diazepam (1 mg/kg, i.p.) a significant increase was 
seen in time spent on the beam and the number of falls (Figure 5A). 
 
Roscovitine does not attenuate seizure severity in the acute 6-Hz mouse model and in the 
focal pilocarpine rat model 
In order to determine the mechanism by which indirubin exerts its anticonvulsant activity, we 
tested a number of compounds in the zebrafish PTZ seizure model having different affinities for 
the primary targets of indirubin, i.e. GSK-3, several cyclin dependent kinases (CDKs) and the aryl 
hydrocarbon receptor (AhR) (Table 1). In general, compounds with greater selectivity towards 
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GSK-3 (BIO-acetoxime, TCS2002 and 1-azakenpaullone) exhibited clear anticonvulsant activity, 
while those more selective towards CDK (olomoucine) or AhR (MeBIO )were inactive. One 
exception however was roscovitine (Figure 6A), a compound that inhibits CDK-5 (and to a lesser 
extent CDK-2), which was modestly active in the zebrafish PTZ assay. The non-selective 
compounds indirubin and aloisine displayed also anticonvulsant actions in zebrafish. 
All together, these findings strongly point towards GSK-3 inhibition as the mechanism of action   
responsible for the anticonvulsant effects of indirubin. However, to rule out the possibility that 
CDK-5 might be involved in the anticonvulsant actions of indirubin, we next investigated whether 
roscovitine is able to exert anticonvulsant effects in the focal pilocarpine rat model and the acute 
corneal 6-Hz stimulation mouse model, the two rodent models in which indirubin exerted potent 
anticonvulsant effects. In this regard, we showed that pilocarpine-induced seizures are not 
significantly attenuated by intrahippocampal perfusion of 10 µM or 100 µM roscovitine (Figure 
6B). Moreover, we showed that roscovitine (1 mg/kg - 10 mg/kg - 50 mg/kg) was not able to protect 
any of the mice against the electrically 6-Hz-induced seizures (40 mA stimulation current) (Figure 
6C). 
 
Anticonvulsant actions of GSK-3 inhibition 
The ineffectiveness of roscovitine in the pilocarpine rat model and in the 6-Hz mouse model 
highlights the idea that indirubin might exert its anticonvulsant properties via GSK-3 inhibition. 
Selective GSK-3 inhibition has however never been directly tested in zebrafish or rodent seizure 
models. Therefore, to further strengthen our hypothesis, targeted knockdown of GSK-3β was 
performed by using antisense MO oligomers as a target validation experiment (Nasevicius and 
Ekker, 2000; Summerton and Weller, 1997). Here, GSK-3β was chosen over GSK-3α because the 
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β isoform is highly expressed in the central nervous system. Importantly, we titered the MO 
concentration so as not to cause any observable gross developmental dysmorphologies that could 
potentially impair locomotor ability (data not shown). In addition, GSK3β knockdown embryos 
and corresponding controls were also video-tracked at 3 dpf, as MO-mediated translational 
inhibition of target proteins is transient, and presumably would no longer sufficiently reduce the 
levels of GSK3β at 7 dpf. The concentration of PTZ was also reduced to 10 mM as 3 dpf embryos 
displayed the highest level of locomotor acitvity at this concentration (data not shown). 
Knockdown of GSK3β attenuated PTZ-induced seizure behavior in a concentration-dependent 
manner (Figure 7). 
Next, two compounds with a greater selectivity towards GSK-3 then indirubin (Table 1) were 
selected, i.e. BIO-acetoxime (Figure 8A), a derivative of indirubin and an inhibitor of both GSK-
3α and GSK-3β and TCS2002 (Figure 8B), a specific GSK-3β inhibitor structurally unrelated to 
indirubin. First, in the zebrafish PTZ seizure assay, analysis of the 1-hour tracking period revealed 
a significant decrease in the PTZ-induced movements when co-administered with 100 μM and 200 
μM (but not 30 µM) BIO- acetoxime (Figure 8A, right panel). This effect was seen from 5 minutes 
onwards. A significant decrease in larval movement was also seen when administering 20 μM or 
30 μM TCS2002 over the complete tracking period, while 10 μM was ineffective (Figure 8B, right 
panel).  
To further validate the role of GSK-3 as a novel anticonvulsant target, BIO-acetoxime and 
TCS2002 were also investigated in several rodent models. Initially, we investigated whether 
systemic i.p. injection of the selective GSK-3 inhibitors is able to change the seizure severity in 
our rat limbic seizure model. Our results show that the pilocarpine-induced seizures are indeed 
significantly attenuated after systemic treatment of 0.5 mg/kg BIO-acetoxime and 0.5 mg/kg 
Commented [PdW9]: These results were already mentioned in 
table 1, sounds strange  as it was already revealed 
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TCS2002 (Fig. 9A, lower panel). Subsequently, BIO-acetoxime and TCS2002 were tested in the 
electrically induced 6-Hz mouse model (48 mA stimulation current). We demonstrated significant 
differences in seizure protection when control animals, receiving only vehicle sham injections, 
were compared with the animals receiving 0.05 mg/kg BIO-acetoxime, 0.5 mg/kg BIO-acetoxime 
or 0.5 mg/kg TCS2002. Treatment with 5 mg/kg BIO-acetoxime, 0.05 mg/kg TCS2002or 5 mg/kg 
TCS2002 were not able to protect the mice against the electrically-induced seizures, resulting in 
U-shaped dose response curves for both GSK-3 inhibitors in the acute 6-Hz mouse model (48 mA 
stimulation current) (Figure 9B).  
 
GSK-3 inhibition is able to exert anticonvulsant effects in fully kindled 6-Hz mice 
Finally, we wanted to know whether GSK-3 inhibition could also exert anticonvulsant actions in 
a clinically more relevant kindling model  in which the brain has undergone long term alterations 
that promote the epileptic state. Initially, 0.5 mg/kg BIO-acetoxime was tested in a batch of fully 
kindled “epileptic” mice (28 mA subconvulsive stimulation current). No differences were 
observed when the mean pre-treatment seizure score was compared with the average post-
treatment score (Figure 10A). Next, systemic administration of 2.5 mg/kg BIO-acetoxime was 
tested in another group of 6-Hz fully kindled “epileptic” FVB/N mice. Our results revealed a 
significant decrease in mean seizure score when the mean pre-treatment score was compared with 
the post-treatment score (Figure 10B). We showed that i.p. injection of 5 mg/kg BIO-acetoxime 
was able to exert pronounced anticonvulsant effects in fully kindled mice (Figure 10C). 
 
 
Discussion 
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Natural product based drugs are nowadays still a successful approach in drug discovery (Swinney 
and Anthony, 2011). Natural products indeed still serve modern medicine because nature seems to 
strike the right balance between selectivity potency and physicochemical properties needed for 
drug discovery (Bennani, 2011). 
The current study is the first scientific report on the translation of the traditional use of I. arrecta 
in the treatment of seizures to a bench approach in zebrafish and rodent models. 
 
Zebrafish bioassay-guided fractionation of the Congolese medicinal plant I. arrecta identifies 
indirubin as its bioactive component 
In the present study we isolated indirubin by applying bioassay-guided fractionation using 
zebrafish as an in vivo seizure model and structural identification using high-resolution mass 
spectrometry and NMR, we isolated indirubin as the bioactive component of I. arrecta. 
Historically, natural product drug discovery was a time and resource-intensive process. Primary 
screening of crude extracts of plants, followed by bioassay-guided fractionation, dereplication of 
active compounds (rapid identification of known compounds) and isolation and structure 
elucidation of novel bioactive compounds can take months to a year to carry out. Dereplication 
has been aided by LC-MS (liquid chromatography-mass spectrometry) systems and natural-
product databases. Also, structure elucidation can now be aided by advances in spectroscopic 
techniques, particularly high-resolution NMR technologies (Eldridge et al., 2002; Koehn and 
Carter, 2005). Recently, zebrafish have proven useful as in vivo model for bioassay-guided 
isolation of natural products. They offer high-throughput assays and only microgram amounts of 
compound or extract are needed (Berry et al., 2007; Challal et al., 2012; Crawford et al., 2008; 
Crawford et al., 2011; Liu et al., 2011; Orellana-Paucar et al., 2012). 
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GSK-3 but probably not CDK-5 is the anticonvulsant target of indirubin 
Indirubin was shown in this study to exert clear anticonvulsant effects in both zebrafish and rodent 
seizure models. Indirubin has been shown to act on several cellular targets, of which the AhR and 
numerous protein kinases, including CDKs and GSK-3 (Hoessel et al., 1999; Knockaert et al., 
2004; Kunikata et al., 2000; Leclerc et al., 2001) seem to be the most prominent. Moreover, 
indirubin represents a novel structure when compared to the current AEDs and so far, no AEDs 
that target protein kinases have been identified. These criteria could be essential for its further 
development as a new AED. Indirubin was initially discovered as the active ingredient of Danggui 
Longhui Wan, a mixture of 11 plants which is used in traditional Chinese medicine to treat chronic 
myelocytic leukaemia. Indeed, although respresenting only a minor constituent, this red colored 
product was found to carry the antileukemic activity of this medicinal plant mixture (Hoessel et 
al., 1999; Leclerc et al., 2001). As previously evidenced, the anti proliferative effect of indirubin 
seems to be the result of the inhibition of CDKs (Hoessel et al., 1999). In this sense, subsequent 
studies have identified indirubin as a potent inhibitor of CDK-5 (Leclerc et al., 2001), although 
not totally devoid of activity towards a few other kinases (Hoessel et al., 1999; Leclerc et al., 
2001). Consequently, indirubin was also identified as a potent inhibitor of GSK-3 (Leclerc et al., 
2001). Pharmacological inhibitors of GSK-3 and some CDKs have a promising potential for 
applications against several neurodegenerative diseases such as Alzheimer’s disease and 
Parkinson’s disease (Bhat et al., 2004; Leclerc et al., 2001; Polychronopoulos et al., 2004; 
Woodgett, 2001). Nevertheless these two neurobiological targets have never been investigated in 
the field of epilepsy. 
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Although our results in zebrafish have pointed towards GSK-3 inhibition as the anticonvulsant 
mechanism of action of indirubin, a possible involvement of CDKs cannot be excluded. GSK-3 
shares indeed many functional properties with CDKs (Flaherty et al., 2000; Martinez et al., 2002). 
Moreover, a number of compounds that were initially developed as GSK-3 inhibitors have been 
shown to also inhibit CDKs in pharmacological doses and vice versa. It is therefore possible that 
some of the effects, assigned to GSK-3 inhibition may be explained by additional inhibition of 
CDKs (Frame and Cohen, 2001). In light of these findings, the presumption could be raised that 
the anticonvulsant effects of BIO-acetoxime and TCS2002, although identified as potent and 
selective GSK-3 inhibitors, might be a result of CDK inhibition. In this regard however, the affinity 
of BIO-acetoxime for CDK-5 and CDK-2 (i.e. two CDKs that BIO-acetoxime has been found to 
inhibit), is respectively 240 and 430 fold lower than its affinity for GSK-3 (Meijer et al., 2003) 
while TCS2002 selectively inhibits GSK-3β and shows even no affinity for CDKs (Saitoh et al., 
2009). In addition, we demonstrated in the current work that the CDK-5 inhibitor roscovitine, 
although slightly effective in the PTZ zebrafish seizure assay, is unable to show any anticonvulsant 
potential in the acute 6-Hz mouse model and in the focal pilocarpine rat model, two acute seizure 
models where indirubin, BIO-acetoxime and TCS2002 exerted potent anticonvulsant effects. 
Moreover, the anticonvulsant spectrum of BIO-acetoxime and TCS2002 as presently demonstrated 
(i.e. anticonvulsant in the 6-Hz mouse model and the pilocarpine rat model and ineffective in the 
mouse i.v. models) is identical to the results obtained for indirubin. All together, these observations 
suggest that the anticonvulsant actions of indirubin are most likely not mediated via CDK-5 
inhibition but rather via GSK-3 inhibition. 
Selective GSK-3 inhibition exerts potent anticonvulsant effects in electrically-induced 
stimulation mouse models and in a chemoconvulsant rat model for limbic seizures 
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In the current study, we provide the first evidence for anticonvulsant effects of selective GSK-3 
inhibition. Indeed, we show that two selective and structurally unrelated GSK-3 inhibitors, i.e. 
BIO-acetoxime and TCS2002, are able to exert potent anticonvulsant effects in acute- and chronic 
electrically-induced models. Initially, systemic administration of BIO-acetoxime (0.05 mg/kg - 0.5 
mg/kg) and TCS2002 (0.5 mg/kg) was able to exert potent anticonvulsant effects in acute 6-Hz-
induced seizures in NMRI mice. Interestingly, BIO-acetoxime which is a non-isoform specific 
GSK-3 inhibitor was also able to attenuate the electrically-induced seizures in kindled mice in a 
dose-dependent manner. The latter results indicate that GSK-3 inhibition also exerts 
anticonvulsant effects in a model for epileptogenesis and is thus able to attenuate seizures even 
after brain excitability has been altered from a normal, healthy condition into an "epileptic" state. 
In addition, we also demonstrated that the GSK-3 inhibitors are able to protect rats against focally-
evoked pilocarpine-induced seizures. GSK-3 inhibition was however not able to lower the seizure 
threshold in systemic mouse models where the chemoconvulsants pilocarpine or PTZ were 
administered i.v. in the tail vein. Although BIO-acetoxime and TCS2002 were ineffective in these 
latter chemoconvulsant screening models, future investigations of these GSK-3 inhibitors in 
additional, chronic models of epilepsy might be advisable. Indeed, the positive results in the acute 
6-Hz model, which is generally recognized as a model for refractory seizures and the fact that these 
inhibitors attenuate the seizures in fully kindled mice justify the further research of GSK-3 as a 
potential new target for the treatment of pharmacoresistant seizures. In this regard, levetiracetam 
was novel in AED discovery in that sense that it was not discovered by the traditional screening 
approach. Indeed, it was found to be inactive against PTZ-induced seizures even at high, 
pharmacologically irrelevant doses (Klitgaard et al., 1998; Löscher and Hönack, 1993; Löscher et 
al., 1998). However, in the kindled rat model, levetiracetam was found to be highly effective in 
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blocking the fully expressed kindled seizures (Klitgaard et al., 1998; Löscher et al., 1998; Matagne 
and Klitgaard, 1998). Later on, it became clear that levetiracetam exerts its anticonvulsant effects 
via a new, innovative mechanism of action, namely via binding to synaptic SV2A and thereby 
influencing synaptic vesicle exocytosis and neurotransmitter release (Bialer and White, 2010; 
Kaminski et al., 2008). In a way, the lack of efficacy of levetiracetam in traditional screening tests 
demonstrates the importance and utility of additional animal models, such as the electrically-
induced models.  
Since our results indicate that GSK-3 inhibition exerts anticonvulsant effects, it might be possible 
that epilepsy and epileptic disorders occur as a result of elevated GSK-3 levels. In this regard, 
increased GSK-3 activity has been linked a few times to epilepsy and phenomena characterizing 
this disorder. For example, it has recently been shown that the absence of dopamine D2 receptors 
in the hippocampus leads to the activation of GSK-3 after systemic administration of kainic acid. 
This results into a higher susceptibility to kainic acid-induced seizures and excitotoxicity of mice 
lacking D2 receptors (Dunleavy et al., 2013; Tripathi et al., 2010). Furthermore, it has been 
evidenced that the expression levels of GSK-3 were increased after pilocarpine-induced status 
epilepticus in rats. Moreover, the same study showed that lovastatin, which is a cholesterol 
lowering drug, was able to reduce mossy fiber sprouting through reversal of these elevated GSK-
3 levels (Lee et al., 2012). Finally, Laforin, a protein that, when mutated, induces Lafora 
Progressive Myoclonus epilepsy which is a fatal, genetic epileptic disorder, has been found to 
activate GSK-3 (Lohi et al., 2005). These studies suggest that increased seizure susceptibility 
might, at least to a certain extent, be the result of increased GSK-3 activity. On the other hand, a 
recent study by Lewerenz and coworkers showed that GSK-3 can be inhibited via 
phosphoinositide3-kinase activation as a result of the activation of the Akt signaling pathway 
Commented [PdW10]: Very long discussion about 
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which is induced by robust neuronal activity and in epileptic hippocampi (Lewerenz et al., 2014). 
Our current study is however the first that investigates the direct anticonvulsant effect of GSK-3 
inhibition. 
 
GSK-3 inhibitors as potential new drug targets for epilepsy treatment 
The close involvement of GSK-3 activity in diverse human pathologies has encouraged many 
researchers to develop inhibitors as therapeutic agents. To date, no selective GSK-3 inhibitors have 
however been developed to treat epilepsy. Nevertheless, valproic acid, a sodium channel blocker 
which is also used to treat bipolar disorder and epilepsy has also been shown to concentration 
dependently inhibit both GSK-3α and GSK-3β (Chen et al., 1999). Also lamotrigine, another 
currently used AED and sodium channel blocker has been shown to provide protection from GSK-
3 facilitated apoptosis in human neuroblastoma cells (Li et al., 2002). The latter findings support 
the idea that modulation of GSK-3 activity may play a therapeutic beneficial role in epilepsy and 
epileptic disorders. The downstream mechanism of action that could be responsible for the 
anticonvulsive effects of GSK-3 inhibition in our hands remains unclear.  
All together, we can state that there is clearly a link between GSK-3 and epilepsy and that GSK-3 
inhibition might thus represent a promising new target for epilepsy treatment. However, it is 
difficult to predict the safety of chronic GSK-3 suppression. GSK-3 has indeed a lot of cellular 
dependents and chronic suppression might therefore lead to a few potential risks. Since most of 
the GSK-3 inhibiting compounds are ATP competitive and hence block the phosphorylation of 
every substrate for GSK-3, potential problems can arise. For example in the heart, GSK-3 seems 
to suppress cardiac hypertrophy and chronic suppression of this enzyme might therefore lead to 
cardiac complications. Furthermore, GSK-3 inhibitors have been shown to increase β-catenin 
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levels in transformed cell lines which may, in turn, increase the propensity for developing certain 
cancers (Woodgett, 2001). The recent development of thiadiazolidinone derivates, which represent 
a group of ATP non-competitive GSK-3 inhibitors, might in this regard be very interesting to 
reduce unwanted side effects. It is however noteworthy to mention that lithium which is, as 
previously mentioned, a well established GSK-3 inhibitor has been used for many years to treat 
bipolar disorder and its long-term use of therapeutic doses is not known to be associated with an 
increased risk of cancer or cardiac complications (Cohen and Goedert, 2004). 
 
Conclusion 
In the current study, we identified the GSK-3 inhibitor indirubin as the bioactive component of the 
plant I. arrecta. We also provide the first evidence for anticonvulsant effects of selective and acute 
GSK-3 inhibition and suggest that GSK-3 might serve as potential new drug target in AED 
discovery. Future research on GSK-3 in epilepsy, including the exploration of the effects of 
chronic GSK-3 inhibition is hence intriguing.  
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Table Legends 
Table 1: MTC values, IC50 values and results of the behavioral PTZ assay in zebrafish. The 
activity in the zebrafish (ZF) PTZ assay is depicted as -, +, ++ or +++ for non active, significantly 
active with p<0.05, p<0.01 and p<0.001, respectively. 
Figure Legends 
Figure 1: Anticonvulsant activity of Congolese methanolic plant extracts and TLC 
separation of constituents of Indigofera arrecta. (A) Graph comparing ability of seven medicinal 
plant extracts to suppress convulsive behavior in the larval zebrafish PTZ seizure assay. Extract 3 
corresponds to Indigofera arrecta. (B) The anticonvulsant activity identified for band (fraction) 
number 3 and (C) the corresponding thin layer chromatogram (TLC) of extract 3. All data were 
evaluated using the unpaired Student’s t-test [*P<0.05;**P<0.01;***P<0.001]. 
Figure 2: Spectral data of indirubin. (A) UV/Vis spectrum, (B) 1H NMR spectra, and (C) 
HRMS (ESI+) of indirubin. 
Figure 3: Behavioral response to indirubin and quantitative EEG outcome of zebrafish 
larvae in conjunction with PTZ. (A) Structural formula of Indirubin. (B) Behavioral response of 
indirubin was tested at three different concentrations: 30 μM, 100 μM and 300 μM. All time 
interval points were compared to the corresponding PTZ control using the unpaired Student’s t-
test. Values that were significantly different from PTZ control are marked [*P<0.05]. Total 
locomotor activity is expressed in actinteg units and averaged for 5-min intervals. The number of 
larvae tested for each concentration is n=24. (C) Indirubin suppresses PTZ induced epileptiform 
discharges as demonstrated by (left panel) the number of interictal-like spikes, (middle panel) 
number of ictal-like spikes and (right panel) total cumulative duration of each type of epileptiform 
activity (ictal and inter-ictal activity) measured. All values expressed as mean ± SEM. Statistical 
significance relative to PTZ control were determined using the unpaired Student’s t-test 
[*P<0.05;**P<0.01;***P<0.001]. The number of recordings analyzed were: Vehicle (n=10), PTZ 
20 mM (n=14) and Indirubin 300 µM + PTZ (n=8). 
Figure 4: Anticonvulsant actions of indirubin in an acute rat and mouse model for epileptic 
seizures. (A) (left panel) Microdialysis protocol. (Right panel) Indirubin suppresses seizures in 
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the focal pilocarpine rat model. Seizure severity is expressed as TSSS (mean ± SEM). Statistics: 
One way ANOVA followed by Newman-Keuls post hoc test [*P<0.05;***P<0.001]. (B) 
Anticonvulsant actions of indirubin against 6-Hz-induced electrical seizures in mice (stimulation 
current = 53 mA). For clarity of presentation, the percentage of protected versus non-protected 
mice is illustrated. Statistics: Chi square test for trend, followed by the Fisher's exact test to denote 
any significant differences between the experimental test groups and the untreated sham group 
[*P<0.05; **P<0.01].  
Figure 5: Indirubin does not alter motor coordination in the mouse beamwalking test. 
Performance of mice in the beamwalking test after treatment with (A) diazepam or (B) indirubin. 
The y-axis denotes (left panel) time on beam (in seconds), (middle panel) number of footslips or 
(right panel) number of falls. The x-axis denotes the treatment dose (1 mg/kg diazepam; 10 mg/kg 
indirubin). Vehicle used was phosphate buffered saline (PBS) and PEG400/H2O for diazepam and 
indirubin respectively. Number of animals used was n=3 for Vehicle and diazepam and n=6 for 
indirubin. All results were evaluated using one-way ANOVA followed by Dunnett’s multiple 
comparison test. [*P<0.05;**P<0.01] 
Figure 6: Roscovitine does not alter seizure severity in an acute rat and mouse model for 
epileptic seizures. (A) Structural formula of roscovitine. (B) (left panel) Microdialysis protocol. 
Roscovitine is inactive in (B) (right panel) the pilocarpine rat model and (C) The acute 6-Hz model 
for refractory seizures (40 mA stimulation current). 
Figure 7: GSK-3β knockdown protects against PTZ-induced convulsions in zebrafish larvae. 
Graph denotes total larval activity (expressed in actinteg units), averaged for 10-min intervals over 
a period of 60 minutes. All time intervals were compared to the corresponding PTZ control using 
the unpaired Student’s t-test. Values that were significantly different from PTZ control are marked 
[*P<0.05;***P<0.001]. The number of larvae tested for each concentration is n=52 for the 
uninjected controls, 10 mM PTZ control group, 200 μM GSK3b MO and for 200 μM GSK3b MO 
+ PTZ. For  300 μM GSK3b MO and 300 μM GSK3b MO + PTZ the number of larvae tested is 
n=48. 
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Figure 8: Behavioral response of zebrafish larvae to BIO-acetoxime and TCS2002 in 
conjunction with PTZ. (A) (left panel) Structural formula of BIO-acetoxime. (right panel) BIO-
acetoxime was tested at three different concentrations: 30 μM, 100 μM and 200 μM. (B) (left 
panel) Structural formula of TCS2002. (right panel) TCS2002 was tested at three different 
concentrations: 10 μM, 20 μM and 30 μM.  
All time interval points were compared to the corresponding PTZ control using the unpaired 
Student’s t-test. Values that were significantly different from PTZ control are marked 
[*P<0.05;**P<0.01;***P<0.001]. Total locomotor activity is expressed in actinteg units and 
averaged for 5-min intervals. The number of larvae tested for each concentration is n=24.  
Figure 9: Anticonvulsant actions of BIO-acetoxime and TCS2002 in rodent models. (A) 
(upper panel) Microdialysis protocol. (lower panel) Anticonvulsant effects of BIO-acetoxime (0.5 
mg/kg) and TCS2002 (0.5 mg/kg) in the focal pilocarpine rat model. Statistics: One way ANOVA 
followed by Bonferroni's post hoc test. [**P<0.01]. (B) Anticonvulsant effects of (left panel) BIO-
acetoxime and (right panel) TCS2002 in the acute 6-Hz mouse model (48 mA stimulation current). 
For clarity of presentation, the percentage of protected vs non protected mice is illustrated. 
Statistics: Chi square test for trend, followed by the Fisher's exact test to denote any significant 
differences between the experimental test groups and the untreated sham group [*P<0.05; 
**P<0.01; ***P<0.001]. 
Figure 10: Anticonvulsant effects of (A) 0.5 mg/kg, (B) 2.5 mg/kg and (C) 5 mg/kg BIO-
acetoxime in 6-Hz fully kindled FVB/N mice (28 mA subconvulsive stimulation current). 
Statistics: Mann-Whitney test [*P<0.05; **P<0.01]. 
 
 
 
 
 
